Similar articles

• [Adriamycin/cyclophosphamide: current standard in adjuvant therapy for breast carcinoma?].

  Sauter C. Sauter C. Schweiz Med Wochenschr. 1994 Oct 29;124(43):1879-81. Schweiz Med Wochenschr. 1994. PMID: 7973513 German. No abstract available.
• [Feasibility of adjuvant high-dose CAF (cyclophosphamide, adriamycin, 5-FU) therapy for primary breast cancer patients].

  Toi M, Hayashi K, Tominaga T. Toi M, et al. Gan To Kagaku Ryoho. 1994 Sep;21(12):2057-60. Gan To Kagaku Ryoho. 1994. PMID: 8085859 Japanese. No abstract available.
• [Comparison of adjuvant chemotherapy in breast carcinoma with a combination of cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and AC (doxorubicin, cyclophosphamide). Initial results of a national cooperative study].

  Pribylová O, Petruzelka L, Honová H, Fischer J, Bustová I, Siffnerová H, Kůta M, Miller V, Hacklová M, Machácek J, Kohoutek M, Vodvárka P, Kyselá T, Tajblová J, Suk J, Dorazilová V, Bauer J. Pribylová O, et al. Sb Lek. 1998;99(1):25-31. Sb Lek. 1998. PMID: 9748796 Clinical Trial. Czech.
• [CMF or CAF combination chemotherapy for breast cancer].

  Ota J. Ota J. Gan To Kagaku Ryoho. 1996 Dec;23(14):1886-90. Gan To Kagaku Ryoho. 1996. PMID: 8978791 Review. Japanese.
• The use of mitoxantrone in the treatment of breast cancer.

  Hainsworth JD. Hainsworth JD. Semin Oncol. 1995 Feb;22(1 Suppl 1):17-20. Semin Oncol. 1995. PMID: 7863347 Review. No abstract available.